Journal
BIOMOLECULES
Volume 12, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/biom12010080
Keywords
gold; breast cancer; Auranofin; phosphane compounds; carbene compounds; IC50; in vivo; in vitro; metal-based drugs; molecular targets
Categories
Ask authors/readers for more resources
This article reviews recent scientific findings on two classes of gold compounds containing phosphane or carbene ligands, as well as the recent developments in the application of Auranofin for breast cancers.
Breast cancers (BCs) may present dramatic diagnoses, both for ineffective therapies and for the limited outcomes in terms of lifespan. For these types of tumors, the search for new drugs is a primary necessity. It is widely recognized that gold compounds are highly active and extremely potent as anticancer agents against many cancer cell lines. The presence of the metal plays an essential role in the activation of the cytotoxicity of these coordination compounds, whose activity, if restricted to the ligands alone, would be non-existent. On the other hand, gold exhibits a complex biochemistry, substantially variable depending on the chemical environments around the central metal. In this review, the scientific findings of the last 6-7 years on two classes of gold(I) compounds, containing phosphane or carbene ligands, are reviewed. In addition to this class of Au(I) compounds, the recent developments in the application of Auranofin in regards to BCs are reported. Auranofin is a triethylphosphine-thiosugar compound that, being a drug approved by the FDA-therefore extensively studied-is an interesting lead gold compound and a good comparison to understand the activities of structurally related Au(I) compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available